Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
hepatocellular_carcinoma [2019/10/18 19:19]
admin [Data]
hepatocellular_carcinoma [2019/10/18 19:50] (current)
admin [Data]
Line 14: Line 14:
   - Sequencing was completed by Beckman Coulter using [[http://​www.illumina.com/​products/​truseq_rna_library_prep_kit_v2.html|TruSeq RNA Library Preparation Kit v2]] which is an unstranded protocol.   - Sequencing was completed by Beckman Coulter using [[http://​www.illumina.com/​products/​truseq_rna_library_prep_kit_v2.html|TruSeq RNA Library Preparation Kit v2]] which is an unstranded protocol.
   - Jielei provided TruSeq {{:​illumina_stranded_rnaseq_mapping.pdf|Stranded}} ​ RNA-Seq data from 8 mice in August 2017 (See ~/​proj/​hcc/​data/​TPT1/​readme.txt),​ which was analyzed using TruSeq Stranded RNA-Seq.   - Jielei provided TruSeq {{:​illumina_stranded_rnaseq_mapping.pdf|Stranded}} ​ RNA-Seq data from 8 mice in August 2017 (See ~/​proj/​hcc/​data/​TPT1/​readme.txt),​ which was analyzed using TruSeq Stranded RNA-Seq.
-  - Gao, Qiang, et al. "​Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma."​ //​[[https://​www.sciencedirect.com/​science/​article/​pii/​S0092867419310037|Cell//​]]//​ 179.2 (2019): 561-577. \\  "The data of WES, transcriptome sequencing, proteome, and phosphoproteome are available in [[https://​www.biosino.org/​node|NODE]] (accession # [[https://​www.biosino.org/​node/​experiment/​detail/​OEX001697|OEP000321]]).+  - Gao, Qiang, et al. "​Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma."​ //​[[https://​www.sciencedirect.com/​science/​article/​pii/​S0092867419310037|Cell//​]]//​ 179.2 (2019): 561-577. \\ "The data of WES, transcriptome sequencing, proteome, and phosphoproteome are available in [[https://​www.biosino.org/​node|NODE]] (accession # [[https://​www.biosino.org/​node/​experiment/​detail/​OEX001697|OEP000321]]). Survival data (~5 years of followup) were included in Table S1.